ABSTRACT
Trojan asteroids are small bodies orbiting around the L4 or L5 Lagrangian points of a Sun-planet system. Due to their peculiar orbits, they provide key constraints to the Solar System evolution models. Despite numerous dedicated observational efforts in the last decade, asteroid 2010 TK7 has been the only known Earth Trojan thus far. Here we confirm that the recently discovered 2020 XL5 is the second transient Earth Trojan known. To study its orbit, we used archival data from 2012 to 2019 and observed the object in 2021 from three ground-based observatories. Our study of its orbital stability shows that 2020 XL5 will remain in L4 for at least 4 000 years. With a photometric analysis we estimate its absolute magnitude to be [Formula: see text], and color indices suggestive of a C-complex taxonomy. Assuming an albedo of 0.06 ± 0.03, we obtain a diameter of 1.18 ± 0.08 km, larger than the first known Earth Trojan asteroid.
ABSTRACT
The study of binary Kuiper Belt objects helps to probe the dynamic conditions present during planet formation in the solar system. We report on the mutual-orbit determination of 2001 QW322, a Kuiper Belt binary with a very large separation whose properties challenge binary-formation and -evolution theories. Six years of tracking indicate that the binary's mutual-orbit period is approximately 25 to 30 years, that the orbit pole is retrograde and inclined 50 degrees to 62 degrees from the ecliptic plane, and, most surprisingly, that the mutual orbital eccentricity is <0.4. The semimajor axis of 105,000 to 135,000 kilometers is 10 times that of other near-equal-mass binaries. Because this weakly bound binary is prone to orbital disruption by interlopers, its lifetime in its present state is probably less than 1 billion years.
ABSTRACT
In this work, an isocratic high-performance liquid chromatographic method for quantitation of liposomal benznidazole (BNZ) in biological tissues is presented. The method comprises protein precipitation together with an efficient extraction of bulk or liposomal BNZ with acetonitrile-dimethylsulfoxide (1:1, v/v) at a 2:1 (extraction solvent-tissue matrix, v/v or /vw) ratio; the process is completed by a final precipitation with trichloroacetic acid. The resultant supernatants are assayed chromatographically using a Kromasil C18 (25- x 0.4-cm i.d., 100 A, 5- microm particle size), with an isocratic mobil phase consisting of acetonitrile-water (40:60, v/v), a flow rate of 0.9 mL/min, and detected at 324 nm. Bulk BNZ is used as a reference standard for the analysis of samples containing liposomal BNZ. The assay is linear over a concentration range of 0.75 (the lowest quantity of analyte determined with precision and accuracy of >or= 20%) to 25 microg/mL-g in all liquid and solid matrices. Within-day precision is better than 6.4% in plasma and 8.6% in liver, the same for the two assayed concentrations. Between-day precision is 5.4% and 12.3% in plasma and 9% and 6.9% in liver for the two assayed concentrations, respectively. The absolute recoveries range between 70% and 97%. Therefore, the method is accurate and precise to be employed for detection of minor quantities of liposomal BNZ in biological tissues.
Subject(s)
Chromatography, High Pressure Liquid/methods , Nitroimidazoles/pharmacokinetics , Kidney/metabolism , Liposomes , Liver/metabolism , Lung/metabolism , Nitroimidazoles/blood , Reproducibility of Results , Sensitivity and Specificity , Spectrophotometry, Ultraviolet , Tissue DistributionABSTRACT
The purpose of this study was to find a multilamellar liposomal formulation for the antichagasic drug Benznidazole (BNZ). Different lipid matrices and organic solvents for BNZ were tested in order to obtain the liposomes with the highest g BNZ/100 g total lipid (D/TL) ratio. The best lipid matrices resulted from hydrogenated phosphatidylcholine from soybean (HSPC): Cholesterol (Chol): distearoyl-phosphatidylglycerol (DSPG) (molar ratio 2:2:1) prepared with BNZ dissolved in DMSO. Drug loading of 2 g BNZ/100 g total lipids at a total lipid concentration of 20-30 mM was obtained. Two in vitro assays on the HSPC:Chol:DSPG formulation to predict its in vivo behaviour were performed. In the first experiments, after 60 min at 1-450-fold dilution in buffer at 37 degrees C, the amount of drug associated to liposomes was reduced from 2 to 0.25 g BNZ/100 g total lipids at a rate of 65% (drug lost) min(-1) at the first minute followed by 0.4% (drug lost) min(-1) during the next hour. When incubated in plasma at 37 degrees C, the HSPC:Chol:DSPG formulations bounded a high amount of plasma proteins: r=2400 microg plasma protein per micromol total lipid.
